Clinical Trials
11
Trial Phases
3 Phases
Drug Approvals
62
Drug Approvals
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- Next
Clinical Trials
Distribution across different clinical trial phases (11 trials with phase data)• Click on a phase to view related trials
Pharmacokinetics and Safety of Cefazolin 3gm DUPLEX in Adults
- Conditions
- Infections
- Interventions
- First Posted Date
- 2022-01-25
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- B. Braun Medical Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT05205486
- Locations
- 🇺🇸
IACT Health - Roswell - IACT - HyperCore - PPDS, Columbus, Georgia, United States
🇺🇸Hightower Clinical, LLC, Oklahoma City, Oklahoma, United States
Resveratrol Excipient Paclitaxel Coated Balloon for Coronary Treatment
- Conditions
- Coronary Artery RestenosisIn-stent Coronary Artery RestenosisIn-stent Restenosis
- First Posted Date
- 2021-10-26
- Last Posted Date
- 2023-02-14
- Lead Sponsor
- B. Braun Medical Inc.
- Registration Number
- NCT05093244
Effect of B. Braun Peripheral Advantage Program on Complications, Indwell Time and First Stick Success of PIVC Therapy
- Conditions
- Complications Associated With Device
- First Posted Date
- 2019-08-07
- Last Posted Date
- 2022-08-01
- Lead Sponsor
- B. Braun Medical Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT04048863
- Locations
- 🇺🇸
Mayo Clinic, La Crosse, Wisconsin, United States
Prontosan Quality of Life Study in Patients With Chronic Leg Wound(s)
- Conditions
- Wound of Lower Leg (Physical Finding)
- First Posted Date
- 2017-12-12
- Last Posted Date
- 2020-12-08
- Lead Sponsor
- B. Braun Medical Inc.
- Target Recruit Count
- 43
- Registration Number
- NCT03369756
- Locations
- 🇺🇸
Jupiter Medical Center, Jupiter, Florida, United States
🇺🇸Barry University Clinical Research, North Miami Beach, Florida, United States
🇺🇸Northwell Comprehensive Wound Care Healing Center and Hyperbarics, N. New Hyde Park, New York, United States
Safety of 1 g and 2 g of Cefazolin in Pediatric Subjects
- Conditions
- Postoperative Infection
- Interventions
- First Posted Date
- 2017-07-27
- Last Posted Date
- 2020-07-13
- Lead Sponsor
- B. Braun Medical Inc.
- Target Recruit Count
- 61
- Registration Number
- NCT03231228
- Locations
- 🇺🇸
Arkansas Children's Research Institute, Little Rock, Arkansas, United States
🇺🇸University of Missouri Health Care System, Columbia, Missouri, United States
🇺🇸Children's Medical Center Dallas, Dallas, Texas, United States
- Prev
- 1
- 2
- 3
- Next
News
FDA Approves B. Braun's Piperacillin and Tazobactam in DUPLEX Drug Delivery System
B. Braun Medical has received FDA approval for Piperacillin and Tazobactam in their DUPLEX Drug Delivery System, offering a more efficient administration method for this widely used antibiotic combination.
B. Braun Introduces Revolutionary Emergency Department Nerve Block Tray to Reduce Opioid Use
B. Braun Medical Inc. has launched the first-ever Emergency Department Single-Shot Nerve Block Tray, featuring the Ultraplex® 360 Needle with advanced echogenic technology for enhanced ultrasound visibility.
B. Braun's Introcan Safety 2 Deep Access IV Catheter Receives FDA Clearance
B. Braun Medical's Introcan Safety 2 Deep Access IV Catheter has received FDA 510(k) clearance, expanding the Introcan Safety 2 portfolio.
FDA Updates: Approvals for RSV Vaccine, Pneumococcal Vaccine, and TB Drug Alongside Device Recalls
• The FDA granted traditional approval to Sirturo (bedaquiline) for treating rifampin- and isoniazid-resistant tuberculosis in adults and children, based on Phase 3 STREAM study data. • mResvia, an mRNA-based vaccine, received FDA approval for preventing lower respiratory tract disease caused by respiratory syncytial virus (RSV) in adults aged 60 years and older. • Capvaxive, a pneumococcal 21-valent conjugate vaccine, was approved for preventing invasive disease and pneumonia caused by Streptococcus pneumoniae in adults 18 years and older. • Several critical care medical devices, including infusion pumps and chest compression devices, were recalled due to potential for serious adverse health consequences.